R. Stupp, W. Mason, M. Van-den-bent, M. Weller, B. Fisher et al., Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma, New England Journal of Medicine, vol.352, issue.10, pp.987-996, 2005.
DOI : 10.1056/NEJMoa043330

K. Plate, G. Breier, H. Weich, and W. Risau, Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo, Nature, vol.359, issue.6398, pp.845-848, 1992.
DOI : 10.1038/359845a0

K. Kim, B. Li, J. Winer, M. Armanini, N. Gillett et al., Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo, Nature, vol.362, issue.6423, pp.841-844, 1993.
DOI : 10.1038/362841a0

H. Friedman, M. Prados, P. Wen, T. Mikkelsen, D. Schiff et al., Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma, Journal of Clinical Oncology, vol.27, issue.28, pp.4733-4740, 2009.
DOI : 10.1200/JCO.2008.19.8721

J. Vredenburgh, A. Desjardins, J. Herndon, M. J. Reardon, D. Quinn et al., Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme, Journal of Clinical Oncology, vol.25, issue.30, pp.4722-4729, 2007.
DOI : 10.1200/JCO.2007.12.2440

O. Chinot, Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date, Expert Review of Anticancer Therapy, vol.12, issue.11, pp.1413-1427, 2012.
DOI : 10.1586/era.12.128

O. Chinot, W. Wick, W. Mason, R. Henriksson, F. Saran et al., Bevacizumab plus Radiotherapy???Temozolomide for Newly Diagnosed Glioblastoma, New England Journal of Medicine, vol.370, issue.8, pp.709-722, 2014.
DOI : 10.1056/NEJMoa1308345
URL : http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-89503

M. Gilbert, J. Dignam, T. Armstrong, J. Wefel, D. Blumenthal et al., A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma, New England Journal of Medicine, vol.370, issue.8, pp.699-708, 2014.
DOI : 10.1056/NEJMoa1308573

S. Sathornsumetee, Y. Cao, J. Marcello, J. Herndon, R. Mclendon et al., Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and Irinotecan, Journal of Clinical Oncology, vol.26, issue.2, pp.271-278, 2008.
DOI : 10.1200/JCO.2007.13.3652
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930173

J. Felsberg, N. Thon, S. Eigenbrod, B. Hentschel, M. Sabel et al., Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas, International Journal of Cancer, vol.379, issue.3, pp.659-670, 2011.
DOI : 10.1002/ijc.26083

A. Brandes, E. Franceschi, A. Tosoni, S. Bartolini, A. Bacci et al., O6-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications, Neuro-Oncology, vol.12, issue.3, pp.283-288, 2010.
DOI : 10.1093/neuonc/nop050
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940594

P. Metellus, B. Coulibaly, I. Nanni, F. Fina, N. Eudes et al., -methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation, Cancer, vol.32, issue.20, pp.4783-4794, 2009.
DOI : 10.1002/cncr.24546
URL : https://hal.archives-ouvertes.fr/hal-00160682

D. Cahill, K. Levine, R. Betensky, P. Codd, C. Romany et al., Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide Treatment, Clinical Cancer Research, vol.13, issue.7, pp.2038-2045, 2007.
DOI : 10.1158/1078-0432.CCR-06-2149

S. Thomas, D. Vries, and G. , Angiogenic Expression Profile of Normal and Neurofibromin-Deficient Human Schwann Cells, Neurochemical Research, vol.6, issue.suppl 3, pp.1129-1141, 2007.
DOI : 10.1007/s11064-007-9279-z

T. Khong, N. Thairu, H. Larsen, P. Dawson, S. Kiriakidis et al., Identification of the angiogenic gene signature induced by EGF and hypoxia in colorectal cancer, BMC Cancer, vol.14, issue.1, p.518, 2013.
DOI : 10.1056/NEJMoa0805019

P. Carmeliet and R. Jain, Molecular mechanisms and clinical applications of angiogenesis, Nature, vol.464, issue.7347, pp.298-307, 2011.
DOI : 10.1038/nature10144

S. Kozin, W. Kamoun, Y. Huang, M. Dawson, R. Jain et al., Recruitment of Myeloid but not Endothelial Precursor Cells Facilitates Tumor Regrowth after Local Irradiation, Cancer Research, vol.70, issue.14, pp.5679-5685, 2010.
DOI : 10.1158/0008-5472.CAN-09-4446

G. Ahn and J. Brown, Matrix Metalloproteinase-9 Is Required for Tumor Vasculogenesis but Not for Angiogenesis: Role of Bone Marrow-Derived Myelomonocytic Cells, Cancer Cell, vol.13, issue.3, pp.193-205, 2008.
DOI : 10.1016/j.ccr.2007.11.032

C. Bastianutto, A. Mian, J. Symes, J. Mocanu, N. Alajez et al., Local Radiotherapy Induces Homing of Hematopoietic Stem Cells to the Irradiated Bone Marrow, Cancer Research, vol.67, issue.21, pp.10112-10116, 2007.
DOI : 10.1158/0008-5472.CAN-07-2192

M. Kioi, H. Vogel, G. Schultz, R. Hoffman, G. Harsh et al., Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice, Journal of Clinical Investigation, vol.120, issue.3, pp.694-705, 2010.
DOI : 10.1172/JCI40283DS1

O. Lerman, M. Greives, S. Singh, V. Thanik, C. Chang et al., Low-dose radiation augments vasculogenesis signaling through HIF-1-dependent and -independent SDF-1 induction, Blood, vol.116, issue.18, pp.3669-3676, 2010.
DOI : 10.1182/blood-2009-03-213629

N. Redjal, J. Chan, R. Segal, and A. Kung, CXCR4 Inhibition Synergizes with Cytotoxic Chemotherapy in Gliomas, Clinical Cancer Research, vol.12, issue.22, pp.6765-6771, 2006.
DOI : 10.1158/1078-0432.CCR-06-1372

M. Aghi, K. Cohen, R. Klein, D. Scadden, and E. Chiocca, Tumor Stromal-Derived Factor-1 Recruits Vascular Progenitors to Mitotic Neovasculature, where Microenvironment Influences Their Differentiated Phenotypes, Cancer Research, vol.66, issue.18, pp.9054-9064, 2006.
DOI : 10.1158/0008-5472.CAN-05-3759

S. Liu, R. Alomran, S. Chernikova, F. Lartey, J. Stafford et al., Blockade of SDF-1 after irradiation inhibits tumor recurrences of autochthonous brain tumors in rats, Neuro-Oncology, vol.16, issue.1, pp.21-28, 2014.
DOI : 10.1093/neuonc/not149

S. Nobusawa, R. Stawski, Y. Kim, Y. Nakazato, and H. Ohgaki, Amplification of the PDGFRA, KIT and KDR genes in glioblastoma: a population-based study, Neuropathology, vol.17, issue.6, pp.583-588, 2011.
DOI : 10.1111/j.1440-1789.2011.01204.x

S. Sjöström, C. Wibom, U. Andersson, T. Brännström, H. Broholm et al., Genetic variations in VEGF and VEGFR2 and glioblastoma outcome, Journal of Neuro-Oncology, vol.48, issue.2, pp.523-527, 2011.
DOI : 10.1007/s11060-010-0504-2

Y. Jung, K. Joo, D. Seong, Y. Choi, D. Kong et al., Identification of prognostic biomarkers for glioblastomas using protein expression profiling, Int J Oncol, vol.40, pp.1122-1132, 2012.

E. Tabouret, O. Chinot, M. Sanson, A. Loundou, K. Hoang-xuan et al., Predictive biomarkers investigated in glioblastoma, Expert Review of Molecular Diagnostics, vol.14, issue.7, pp.883-893, 2014.
DOI : 10.1586/14737159.2014.945436

J. Raizer, S. Grimm, M. Chamberlain, M. Nicholas, J. Chandler et al., A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas, Cancer, vol.72, issue.15S, pp.5297-5305, 2010.
DOI : 10.1002/cncr.25462

E. Galanis, S. Anderson, J. Lafky, J. Uhm, C. Giannini et al., Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial, Clinical Cancer Research, vol.19, issue.17, pp.4816-4823, 2013.
DOI : 10.1158/1078-0432.CCR-13-0708

S. Sathornsumetee, A. Desjardins, J. Vredenburgh, R. Mclendon, J. Marcello et al., Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma, Neuro-Oncol, vol.12, pp.1300-1310, 2010.

E. Tabouret, F. Boudouresque, M. Barrie, M. Matta, C. Boucard et al., Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma, Neuro-Oncology, vol.16, issue.3, pp.392-399, 2014.
DOI : 10.1093/neuonc/not226

J. Quick, F. Gessler, S. Dützmann, E. Hattingen, P. Harter et al., Benefit of tumor resection for recurrent glioblastoma, Journal of Neuro-Oncology, vol.68, issue.3, pp.365-372, 2014.
DOI : 10.1007/s11060-014-1397-2

M. Oppenlander, A. Wolf, L. Snyder, R. Bina, J. Wilson et al., An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity, Journal of Neurosurgery, vol.120, issue.4, pp.846-853, 2014.
DOI : 10.3171/2013.12.JNS13184

D. Louis, H. Ohgaki, O. Wiestler, W. Cavenee, P. Burger et al., The 2007 WHO Classification of Tumours of the Central Nervous System, Acta Neuropathologica, vol.64, issue.2, pp.97-109, 2007.
DOI : 10.1007/s00401-007-0243-4

D. Figarella-branger, K. Mokhtari, C. Dehais, A. Jouvet, E. Uro-coste et al., Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations, Neuro-Oncology, vol.16, issue.9, pp.1244-1254, 2014.
DOI : 10.1093/neuonc/nou047

P. Wen, D. Macdonald, D. Reardon, T. Cloughesy, A. Sorensen et al., Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group, Journal of Clinical Oncology, vol.28, issue.11, pp.1963-1972, 2010.
DOI : 10.1200/JCO.2009.26.3541

A. Schroeder, O. Mueller, S. Stocker, R. Salowsky, M. Leiber et al., The RIN an RNA integrity number for assigning integrity values to RNA measurements, BMC Molecular Biology, vol.7, issue.1, p.3, 2006.
DOI : 10.1186/1471-2199-7-3

M. Pfaffl, A new mathematical model for relative quantification in real-time RT-PCR, Nucleic Acids Research, vol.29, issue.9, p.45, 2001.
DOI : 10.1093/nar/29.9.e45

V. Valente, S. Teixeira, L. Neder, O. Okamoto, S. Oba-shinjo et al., Selection of suitable housekeeping genes for expression analysis in glioblastoma using quantitative RT-PCR, BMC Molecular Biology, vol.10, issue.1, p.17, 2009.
DOI : 10.1186/1471-2199-10-17

F. Denizot and R. Lang, Rapid colorimetric assay for cell growth and survival, Journal of Immunological Methods, vol.89, issue.2, pp.271-277, 1986.
DOI : 10.1016/0022-1759(86)90368-6